Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS01ADC and SBRT in Localized Prostate Cancer
NCT05361798Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2023
- Primary completion
- Aug 2027
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NHS-IL-12 in prostate cancer (PCa) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and Tolerated Doses of PDS01ADC and SBRT and T-cell clonality. Started Jun 2023; status: recruiting.
02
Drugs
NHS-IL-12
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05361798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361798.